FDA yet to improve safety after Vioxx scandal
The FDA still hasn’t restructured its staff to better monitor drug safety, more than three years after experts recommended key changes in the wake of the Vioxx scandal.
December 9, 2009
Hearings may wait on govs' testimony in Vioxx case
Associated Press - July 27, 2007 12:34 PM ET NEW ORLEANS (AP) - Arguments on two questions in federal Vioxx cases may wait on testimony from two governors who have worked in or for the drug
Journal editors to be deposed ahead of next Vioxx trials
A current editor and former editor of the New England Journal of Medicine, which last month criticized drug maker Merck & Co. for withholding data from a published study on its withdrawn painkiller Vioxx, will be grilled next week by the company's lawyers.
Merck: Don't Mention Vioxx in Voicemails
Merck & Co. has agreed to tell its U.S. employees to immediately stop leaving messages about the painkiller Vioxx on the drug company's voicemail system, according to an order from a New Jersey judge.
